Skip to main content

What the FDA labels say about taking them together

Sevelamer and tecovirimat

Tecovirimat's FDA label of December 31, 2025 names sevelamer in its drug interactions section; the sevelamer labels PlainMeds reads (2) do not name tecovirimat. The tecovirimat label: “Monitor for signs or symptoms of adverse effects when TPOXX is co-administered with phosphate binders.”

Check it at the source: the sevelamer FDA label on DailyMed (effective November 25, 2025, Sanofi-Aventis U.S. LLC); the tecovirimat FDA label on DailyMed (effective December 31, 2025, SIGA Technologies, Inc.).

What does the sevelamer label say about tecovirimat?

Sevelamer's label (effective November 25, 2025) and its 1 other brand-application label do not name tecovirimat in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Sevelamer Carbonate), Sanofi-Aventis U.S. LLC, effective November 25, 2025 (SPL set 3abc32fe-1bfc-4759-8f7c-36095e221b06), via openFDA; the full label on DailyMed

What does the tecovirimat label say about sevelamer?

Tecovirimat label, drug interactions

Concomitant Drug Class/Drug Name: Calcium acetate Lanthanum carbonate Sevelamer carbonate Sucroferric oxyhydroxide; Effect on Concentration a: ↑ tecovirimat; Clinical Effect/Recommendation: Monitor for signs or symptoms of adverse effects when TPOXX is co-administered with phosphate binders [see Overdose ()].

Source: FDA drug label (TPOXX), SIGA Technologies, Inc., effective December 31, 2025 (SPL set fce826ab-4d6a-4139-a2ee-a304a913a253), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

35Sevelamer generic labelers
0Tecovirimat generic labelers
SevelamerTecovirimat
Labeled forn/an/a
Boxed warningNoNo
Pharmacy cost (NADAC)$0.214 per tablet 800 mg tabletn/a
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?